Cabozatininb for Prostate Cancer – pro
A recent COMET-1 blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC in men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide who were randomly assigned at a two-to-one ratio to cabozantinib 60 mg once per day or prednisone 5 mg twice per day, did not show an improved survival over prednsione alone.Clearly, more studies need to be done before this drug becomes routine i
Butler, Sara K. Cabozantinib (Cabometyx®). Oncology Times: June 25th, 2017 – Volume 39 – Issue 12 – p 15,37–37
Matthew Smith, Johann De Bono, Cora Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1, Journal of Clinical Oncology 34, no. 25 (September 2016) 3005-3013.
NCCN, Prostate Cancer 2017